Key result
Reflexive treatment of asymptomatic severe hypertension causes harm, requiring parenteral therapy only for true emergencies.
Why the study?
Appropriate management of acute, severe blood pressure elevation depends on distinguishing hypertensive emergency with acute target-organ damage from severe hypertension without acute target-organ damage, which is harmed by rapid pressure reduction. Recent guideline updates retired older terminology and recommended against reflexive intravenous or as-needed oral therapy in asymptomatic patients.
This practice update reinforces 2024-2025 AHA/ACC guidelines that retire the term 'hypertensive urgency' and classify rapid blood pressure lowering in asymptomatic severe hypertension as harmful (Class 3: Harm), emphasizing treatment based on acute target-organ damage rather than blood pressure numbers alone.
Answers are grounded in this paper and cite their sources.
Supports shift from number-based to organ-damage assessment in severe hypertension; extends 2024-2025 guideline synthesis with bedside protocols.
Acute, severe elevation of blood pressure is a frequent reason for emergency-department and inpatient evaluation, yet appropriate management turns on a single pivotal distinction: whether acute, ongoing target-organ damage is present.Hypertensive emergency-severe hypertension (typically >180/120 mm Hg) accompanied by new or progressive injury to the brain, heart, kidneys, retina, or large arteries-requires prompt, controlled, parenteral blood-pressure reduction in a monitored setting.By contrast, severe hypertension without acute target-organ damage, the entity formerly termed "hypertensive urgency, " carries low short-term risk and is harmed rather than helped by rapid pressure reduction.The 2025 ACC/AHA Multisociety Guideline formally retires the term "hypertensive urgency, " and the 2024 AHA scientific statement on acute-care blood pressure adopts the neutral phrase "asymptomatic markedly elevated inpatient blood pressure, " reflecting evidence that reflexive intravenous or as-needed oral therapy in asymptomatic patients precipitates hypotension, acute kidney injury, falls, and prolonged hospitalization (a 2025 Class 3: Harm recommendation).This practice update reviews contemporary definitions and staging; the autoregulatory pathophysiology that makes abrupt lowering hazardous in chronically hypertensive patients; a structured bedside evaluation combining accurate measurement with the BARKH screen (Brain, Arteries, Retina, Kidney, Heart); and organspecific parenteral targets for true emergencies.It contrasts these with an outpatient intensification strategy-trigger reversal, single-pill combination therapy, and close follow-up-for asymptomatic severe hypertension, and highlights emerging tools including the PREVENT risk calculator, pharmacistled titration, and risk-stratified, guideline-directed care.The central message for the bedside clinician is to treat the organ, not merely the number.
No takes yet. Share an insight, caveat, or question.
Parag Rana (2026) conducted a review in Hypertensive emergency and severe hypertension without acute target-organ damage. Controlled parenteral blood-pressure reduction (for hypertensive emergency) or outpatient intensification strategy (for asymptomatic severe hypertension) vs. Reflexive intravenous or as-needed oral antihypertensive therapy in asymptomatic patients was evaluated. Reflexive IV or PRN oral therapy for asymptomatic severe hypertension (>180/120 mm Hg) causes harm (2025 Class 3 recommendation), whereas true emergencies require parenteral reduction.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: